Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 1
F·Filter
Reset allT3·Expert-primary work
Domain-expert primary sources outside the journal pipeline — lectures, podcasts, position papers.
1 source
- 2026Cohortmoderate
Semaglutide is associated with improved breast cancer survival, lower metastatic burden, and a dose-survival relationship uncoupled from weight-loss magnitude
Murugadoss K, Venkatakrishnan AJ, Soundararajan V · medRxiv (preprint)
In a federated EHR network of nearly 29 million patients with 1:1 propensity-matched pooled-comparator analyses, semaglutide-treated breast cancer patients had 54 deaths/2,433 (2.2%) versus 395 deaths/2,433 (16.2%) in metformin/SGLT2i/DPP4i comparators over 24 months (log-rank P<0.001); high-dose semaglutide (≥1.7 mg) had ~1.0% event rate vs ~4.5% in low-dose (0.25–1.0 mg, P=0.034), while weight-loss strata did not separate survival (P=0.22) — and any-metastasis incidence was 7.0% vs 15.0% (rate ratio 0.5, P<0.001).